No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
Abstract Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | Neurological Research and Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42466-023-00277-1 |
| _version_ | 1797451000005525504 |
|---|---|
| author | Laura de Boni Alexandru Odainic Natalie Gancarczyk Luisa Kaluza Christian P. Strassburg Xenia A. K. Kersting Ullrich Wüllner Susanne V. Schmidt Gabor C. Petzold |
| author_facet | Laura de Boni Alexandru Odainic Natalie Gancarczyk Luisa Kaluza Christian P. Strassburg Xenia A. K. Kersting Ullrich Wüllner Susanne V. Schmidt Gabor C. Petzold |
| author_sort | Laura de Boni |
| collection | DOAJ |
| description | Abstract Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation. |
| first_indexed | 2024-03-09T14:48:36Z |
| format | Article |
| id | doaj.art-af2252d4dd924aa9922384f90726bf25 |
| institution | Directory Open Access Journal |
| issn | 2524-3489 |
| language | English |
| last_indexed | 2024-03-09T14:48:36Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Neurological Research and Practice |
| spelling | doaj.art-af2252d4dd924aa9922384f90726bf252023-11-26T14:38:25ZengBMCNeurological Research and Practice2524-34892023-09-01511410.1186/s42466-023-00277-1No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headacheLaura de Boni0Alexandru Odainic1Natalie Gancarczyk2Luisa Kaluza3Christian P. Strassburg4Xenia A. K. Kersting5Ullrich Wüllner6Susanne V. Schmidt7Gabor C. Petzold8Institute of Aerospace Medicine, German Aerospace CenterInstitute of Innate Immunity, University Hospital BonnDivision of Vascular Neurology, Department of Neurology, University Hospital BonnDivision of Vascular Neurology, Department of Neurology, University Hospital BonnDepartment of Internal Medicine I, University Hospital BonnDepartment of Psychiatry and Psychotherapy, University Hospital MainzGerman Center for Neurodegenerative Diseases (DZNE)Institute of Innate Immunity, University Hospital BonnDivision of Vascular Neurology, Department of Neurology, University Hospital BonnAbstract Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation.https://doi.org/10.1186/s42466-023-00277-1Post-acute sequelae of SARS-CoV-2 infectionpost-COVID-19HeadacheNfLGFAPUCH-L1 |
| spellingShingle | Laura de Boni Alexandru Odainic Natalie Gancarczyk Luisa Kaluza Christian P. Strassburg Xenia A. K. Kersting Ullrich Wüllner Susanne V. Schmidt Gabor C. Petzold No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache Neurological Research and Practice Post-acute sequelae of SARS-CoV-2 infection post-COVID-19 Headache NfL GFAP UCH-L1 |
| title | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
| title_full | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
| title_fullStr | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
| title_full_unstemmed | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
| title_short | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
| title_sort | no evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of neuro covid 19 patients with long term persistent headache |
| topic | Post-acute sequelae of SARS-CoV-2 infection post-COVID-19 Headache NfL GFAP UCH-L1 |
| url | https://doi.org/10.1186/s42466-023-00277-1 |
| work_keys_str_mv | AT lauradeboni noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT alexandruodainic noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT nataliegancarczyk noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT luisakaluza noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT christianpstrassburg noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT xeniaakkersting noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT ullrichwullner noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT susannevschmidt noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT gaborcpetzold noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache |